Literature DB >> 12615715

Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.

William C Reinhold1, Hosein Kouros-Mehr, Kurt W Kohn, Alika K Maunakea, Samir Lababidi, Anna Roschke, Kristen Stover, Jes Alexander, Panayotis Pantazis, Lance Miller, Edison Liu, Ilan R Kirsch, Yoshimasa Urasaki, Yves Pommier, John N Weinstein.   

Abstract

To study the molecular mechanisms by which drug resistance develops, we compared DU145 humanprostate cancer cells with a subline selected for resistance to camptothecin. Differences in gene expression level were assessed by hybridizing the two cell types against each other using quadruplicate "Oncochip" cDNA microarrays that included 1648 cancer-related genes. Expression levels differing by a factor of >1.5 were detected for 181 of the genes. These differences were judged statistically reliable on the basis of a stratum-adjusted Kruskal-Wallis test, after taking into account a dye-dependent variable. The 181 expression-altered genes included a larger than expected number of the "apoptosis-related" genes (P = 0.04). To assess whether this observation reflected a generalized resistance of RCO.1 to apoptosis, we exposed the cells to a range of stresses (cisplatin, staurosporine, UV, ionizing radiation, and serum starvation) and found greatly reduced apoptotic responses for RC0.1 (relative to DU145) using flow cytometric Annexin V and terminal deoxynucleotidyl transferase-mediated nick end labeling assays. We next examined the apoptosis-related genes in the context of a molecular interaction map and found expression differences in the direction "expected" on the basis of the apoptosis-resistance of RC0.1 for BAD, caspase-6, and genes that signal via the Akt pathway. Exposure of the cells to wortmannin, an inhibitor of the Akt effector phosphatidylinositol 3-kinase, provided functional support for involvement of the Akt pathway. However, closer examination of the molecular interaction map revealed a paradox: many of the expression differences observed for apoptosis-related genes were in the direction "contrary" to that expected given the resistance of RC0.1. The map indicated that most of these unexpected expression differences were associated with genes involved in the nuclear factor kappa B and transforming growth factor beta pathways. Overall, the patterns that emerged suggested a two-step model for the selection process that led to resistance in RC0.1 cells. The first hypothesized step would involve a decrease in apoptotic susceptibility through changes in the apoptosis-control machinery associated with the Bcl-2 and caspase gene families, and also in antiapoptotic pathways operating through Akt/PKB. The second step would involve changes in multifunctional upstream genes (including some genes in the nuclear factor kappa B and transforming growth factor beta pathways) that can facilitate apoptosis but that would also tend to contribute to cell proliferation in the presence of drug. Thus, we propose that a downstream blockade of apoptosis was "permissive" for the selection of upstream pathway changes that would otherwise have induced apoptosis. This model is analogous to one suggested previously for the relationship between oncogene function and apoptosis in carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615715

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.

Authors:  Chengguo Xing; Liangyou Wang; XiaoHu Tang; Yuk Y Sham
Journal:  Bioorg Med Chem       Date:  2006-12-14       Impact factor: 3.641

Review 2.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

3.  Development of dimeric modulators for anti-apoptotic Bcl-2 proteins.

Authors:  Liangyou Wang; Fansen Kong; Candis L Kokoski; David W Andrews; Chengguo Xing
Journal:  Bioorg Med Chem Lett       Date:  2007-10-30       Impact factor: 2.823

4.  Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission.

Authors:  Olivier Sordet; Abby Goldman; Christophe Redon; Stéphanie Solier; V Ashutosh Rao; Yves Pommier
Journal:  J Biol Chem       Date:  2008-06-13       Impact factor: 5.157

5.  Comparison of caspase-3 activation in tumor cells upon treatment of chemotherapeutic drugs using capillary electrophoresis.

Authors:  Shuang Sha; Honglin Jin; Xiao Li; Jie Yang; Ruiting Ai; Jinling Lu
Journal:  Protein Cell       Date:  2012-04-20       Impact factor: 14.870

Review 6.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

7.  In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation.

Authors:  Ogechi N Ikediobi; Mark Reimers; Steffen Durinck; Paul E Blower; Andrew P Futreal; Michael R Stratton; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2008-06-04       Impact factor: 6.261

8.  Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis.

Authors:  Yide Mei; Chongwei Xie; Wei Xie; Xu Tian; Mei Li; Mian Wu
Journal:  Neoplasia       Date:  2007-10       Impact factor: 5.715

9.  Immunohistochemical expression of caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6 as well as Bcl-2 in benign epithelium and cancer of the prostate.

Authors:  Ramesh Ummanni; Ulrike Lehnigk; Uwe Zimmermann; Christian Woenckhaus; Reinhard Walther; Jürgen Giebel
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

10.  A formal MIM specification and tools for the common exchange of MIM diagrams: an XML-Based format, an API, and a validation method.

Authors:  Augustin Luna; Evrim I Karac; Margot Sunshine; Lucas Chang; Ruth Nussinov; Mirit I Aladjem; Kurt W Kohn
Journal:  BMC Bioinformatics       Date:  2011-05-17       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.